India’s pharmaceutical and healthcare industry anticipates a significant fundraising surge, projecting Rs 12,000-13,000 crore through IPOs in the coming months. Approximately 15 firms, including Indira IVF and Sahajanand Medical Technologies, are preparing to enter the primary market. Investor interest is fueled by rising infertility awareness, favorable demographics, and a shift in global focus towards pharma and biotech innovation.
